Delphia (USA)’s Milestone Pharmaceuticals MIST Stock Holding History

Delphia (USA)’s Portfolio MIST Stock Details MIST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,610	Closed	-$49.9K	–	307
2022 Q4	$49.9K	Buy	+12,610	New	+$66.4K	0.06%	266

Other funds holding MIST

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

AFA

Alta Fundamental Advisers New York $265M AUM 98.61% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Delphia (USA)'s MIST Position: Q1 2023 in Review

Delphia (USA) sold out of Milestone Pharmaceuticals (MIST) in Q1 2023, closing a stake of 12,610 shares — an estimated $49.9K sold.

Delphia (USA) first reported a position in MIST in Q4 2022 and held it in 1 quarter. The position peaked at $49.9K in Q4 2022. 50 funds tracked by Wall St. Rank hold MIST as of Q1 2023.

Delphia (USA) reported no remaining Milestone Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Delphia (USA) sold 12,610 Milestone Pharmaceuticals shares in Q1 2023, an estimated $49.9K.
Delphia (USA) first reported a position in Milestone Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Delphia (USA)'s Milestone Pharmaceuticals position peaked at $49.9K in Q4 2022.
50 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2023.

Based on Delphia (USA)'s 13F filing for Q1 2023, filed 15 May 2023.